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LYMPHOID NEOPLASIA
Novel role of prostate apoptosis response-4 tumor
suppressor in B-cell chronic lymphocytic leukemia
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Natarajan Muthusamy,4,5 Vivek M. Rangnekar,1-3 and Subbarao Bondada1,2
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KEY PO INT S
l CLL cells overexpress
a well-defined tumor
suppressor Par-4,
which promotes
malignant B-CLL
growth and is
regulated through
BCR signaling.
l Robust regulation of
cell-cycle modulator
p21/WAF1 by Par-4 in
CLL cells.
Prostate apoptosis response-4 (Par-4), a proapoptotic tumor suppressor protein, is down-
regulated in many cancers including renal cell carcinoma, glioblastoma, endometrial, and
breast cancer. Par-4 induces apoptosis selectively in various types of cancer cells but not
normal cells. We found that chronic lymphocytic leukemia (CLL) cells from human patients
and from Em-Tcl1 mice constitutively express Par-4 in greater amounts than normal B-1 or
B-2 cells. Interestingly, knockdown of Par-4 in human CLL-derived Mec-1 cells results in a
robust increase in p21/WAF1 expression and decreased growth due to delayed G1-to-S
cell-cycle transition. Lack of Par-4 also increased the expression of p21 and delayed CLL
growth in Em-Tcl1 mice. Par-4 expression in CLL cells required constitutively active B-cell
receptor (BCR) signaling, as inhibition of BCR signaling with US Food and Drug Adminis-
tration (FDA)–approved drugs caused a decrease in Par-4messenger RNA and protein, and
an increase in apoptosis. In particular, activities of Lyn, a Src family kinase, spleen tyrosine
kinase, and Bruton tyrosine kinase are required for Par-4 expression in CLL cells, sug-
gesting a novel regulation of Par-4 through BCR signaling. Together, these results suggest that Par-4 may play a
novel progrowth rather than proapoptotic role in CLL and could be targeted to enhance the therapeutic effects of
BCR-signaling inhibitors. (Blood. 2018;131(26):2943-2954)
Introduction
Chronic lymphocytic leukemia (CLL) is defined by accumulation
of clonally expanded CD51 and CD191 B lymphocytes in blood,
bone marrow, and secondary lymphoid organs with impaired
apoptotic mechanisms.1-4 CLL can be classified into mutated
(M-CLL) and unmutated (U-CLL) forms based on the extent of
mutation in the B-cell receptor (BCR) variable region genes. The
U-CLL group exhibits increased BCR signaling, more aggressive
disease, and worse prognosis.2 Recently, BCR signaling in CLL
has become one of the most promising therapeutic targets after
successful clinical trials with multiple kinase inhibitors,3 as it is
required for the survival of malignant B cells and is constitutively
activated in CLL.3,4 Small molecule inhibitors toward Bruton
tyrosine kinase (Btk) and phosphatidylinositol-3 kinase (PI3K) have
led to higher overall response rates in patients, but complete re-
sponses are rare, necessitating further studies.5
Prostate apoptosis response-4 (Par-4) is a tumor suppressor that
is downregulated by promoter methylation in ;30% of endo-
metrial cancers and acute lymphoblastic leukemia.6,7 It was originally
identified by its upregulation during apoptosis of prostate cancer
cells and later shown to have a cancer-selective mechanism of
inducing cell death through a specific selective for apoptosis
of cancer (SAC) domain.8 Par-4 is activated by protein kinase A
(PKA) phosphorylation allowing Par-4 to translocate to the nu-
cleus and inhibit NF-kB activity in cancer cells but not normal
cells.9 Par-4 directly interacts with Wilms tumor-1 protein,10 and
downregulates Bcl-2 in nonhematopoietic cells.11,12 Par-4 is also
secreted from cells and induces apoptosis by activating the
Fas-signaling pathway through binding to the extracellular re-
ceptor, GRP78.13 A study by Chow et al suggested that CLL pa-
tients who express high levels of Par-4 respond better to imatinib
treatment.14 A 2011 study found increased Par-4 expression in
CD381CLL subgroupand advanced-stagepatients, although such
a correlation was not found in another study.12,15
Here, we sought to understand the role of Par-4 in CLL and the
regulatory mechanisms underlying its expression in CLL using
the Em-Tcl1mousemodel. Thismouse develops aCLL-likedisease
by 9 to 13 months of age, due to a B-cell–specific overexpression
of the oncogene, T-cell leukemia 1 (Tcl1).16 ElevatedTcl1 expression
is associated with the more aggressive forms of CLL in human
patients.17 Surprisingly, we observed that CLL cells express more
Par-4 protein and messenger RNA (mRNA) than all normal B-cell
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subsets studied. Similarly, human CLL samples have elevated
levels of Par-4 protein compared with normal donors. Because
CLL cell survival requires tonic BCR signaling,18 we hypothesized
that BCR signaling may regulate constitutive Par-4 expression in
CLL cells. Our studies support this hypothesis and show that
Par-4 plays a novel progrowth rather than a proapoptotic role
in CLL.
Materials and methods
CLL patients
Human patients with CLL were recruited from the Hematology
and Oncology Clinics at the University of Kentucky (UK) and The
Ohio State University (OSU). The diagnosis of CLL was confirmed
by board-certified hematologists. Each patient gave informed
consent, approved through the UK or OSU Institutional Review
Boards in accordance with the Declaration of Helsinki. UK pa-
tient information was confirmed through a linkage with the
Kentucky Cancer Registry performed by the Markey Cancer
Center (MCC) Cancer Research Informatics Shared Resource
Facility. Peripheral blood CLL cells were purified through Ficoll-
Paque density gradients and confirmed for CLL phenotype by
CD451CD51CD191 staining via flow cytometry. Healthy control
donors were obtained from leukopak units purchased from the
Kentucky Blood Bank (Lexington, KY) after quality testing. Human
cells were cultured in complete RPMI 1640 media.
Mice
Em-Tcl1 and Par-42/2 mice were described previously and were
bred in-house.16,19,20 C57BL/6J and NOD-scid IL2rgnull SCF/GM-
CSF/IL3 (NSGS) mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME) and bred in-house. NOD scid IL2rgnull (NSG)
mice were obtained from The Jackson Laboratory. Par-42/2Tcl1
mice were generated by crossing Par-42/2 mice to Em-Tcl1 mice,
both of which were of C57BL/6J background. Adoptive transfer
models were carried out by injecting C57BL/6J mice with 103 106
Ficoll-Paque purified splenic Em-Tcl1 CLL cells IV via retro-orbital
route. CLL development was monitored through submandibular
vein bleeding.21 When the percentage of CD51CD191 cells in the
peripheral blood was .70%, Em-Tcl1 mice were carefully moni-
tored for moribund body conditions and euthanized accordingly.
Cells were isolated from the spleen of Em-Tcl1mice and confirmed
for the CLL phenotype (CD51CD191) by flow cytometry (supple-
mental Figure 1A, available on the Blood Web site).
Cell survival and proliferation assays
Cell survival and proliferation were determined by the 3-(4,5-
dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT)
assay.22 Primary mouse and human CLL cells (2 3 105 cells per
well) or Mec-1/OSU-CLL cells (2 3 104 cells per well) were
cultured in 96-well flat-bottom plates in 200 mL. The cells were
treated with 0 to 40 mM dasatinib, fostamatinib, or ibrutinib
dissolved in dimethyl sulfoxide (DMSO) for 48 hours and in-
cubated with 0.5 mg/mL MTT for 4 hours followed by solubili-
zation and spectrophotometric measurements at 560 nm and
690 nm. DMSO concentration did not exceed 0.02% of culture
medium and had no measurable effect on cell viability.
shRNA lentiviral infection
Mec-1 CLL cells were transduced with lentiviruses expressing
Lyn short hairpin RNA (shRNA) and Par-4 shRNA. Lyn shRNA
gene sets were purchased through ThermoFisher Scientific. Par-4
shRNA constructs were expressed in the pLKO.1 lentiviral vector.
Lentiviral particles from the supernatants were transduced into
Mec-1 cells in complete Iscovemodified Dulbecco’s mediumwith
10mg/mL Polybrene by centrifugation for 90minutes at 2800 rpm
at 10°C. After 24 hours at 37°C, cells were transferred to fresh
media and selected by puromycin resistance. Gene-silencing
efficiency was analyzed by immunoblotting for respective pro-
teins. Control shRNA and Par-4 shRNA Mec-1 cell growth rates
were monitored by counting total cell numbers at each passage.
Individual control and Par-4 shRNA-expressing clones were iso-
lated by limiting dilution in the presence of puromycin.
In vivo tumor study
Mec-1 cells (2 3 106) expressing Par-4 shRNA or control shRNA
were injected subcutaneously into the right or left flanks of
6 NSGS mice, respectively, with a 1:1 ratio of Matrigel in a
100-mL volume. Tumor size was measured using electronic caliper
and tumor volumes were calculated by length (in millimeters) by
width-squared (in millimeters). Prior to injection, Par-4 knockdown
was verified by immunoblot analysis.
Additional materials and methods can be found in supplemental
Materials and methods.
Results
Em-Tcl1 CLL cells have elevated expression of Par-4
Constitutive Par-4 expression has been described in CLL cells,
butmost previous studies compared CLL cells to peripheral blood
B cells.12,15 Whole-blood B cells are mostly made of the B-2 cell
subset, but B-1a cells are the likely cells of origin for U-CLL andEm-
Tcl1 CLL.23,24 Hence, we isolated CD51CD191 CLL cells from the
spleens of Em-Tcl1 mice and B-cell subsets from the peritoneum
and spleen of C57/BL6J wild-type (WT) mice by fluorescence-
activated cell sorting into specific populations of B-1a (CD191
CD51CD11b1), B-1b (CD191CD52CD11b1), and B-2 (CD191
CD52CD11b2) cells (supplemental Figure 1B).25 Immunoblot and
polymerase chain reaction (PCR) analysis indicated that Em-Tcl1
CLL cells expressed higher levels of Par-4 protein andmRNA than
all of the normal B-cell subsets (Figure 1A-B). B-1a cells expressed
more Par-4 compared with the other B-cell populations but only
;33% of the observed levels in CLL. Because Em-Tcl1 CLL cells
overexpress the oncogene Tcl1, we questioned whether the in-
creased Par-4 expression in CLL cells was associated with Tcl1
levels. WT B-1a with no detectable Tcl1 expressed more Par-4
than Em-Tcl1 B-2 cells with measurable Tcl1 (supplemental
Figure 1C). Despite substantial Tcl1 expression by all Em-Tcl1
B-cell subsets, Par-4 protein levels were not as high as spleen cells
from Em-Tcl1 mice with .90% CD51CD191 CLL cells. CD51
CD191 B-cell percentage in the peripheral blood and spleen
increased with the age of Em-Tcl1mice26 and immunoblot analysis
of whole spleen cells from Em-Tcl1 mice of different ages in-
dicated that Par-4 protein expression increased with CLL burden
(Figure 1C). There was a positive association between leukemic
burden and Par-4 (r2 5 0.7495; P , .0055) (Figure 1D) but not
with levels of Tcl1 when both proteins were normalized to b-actin
(r2 5 0.003958; P 5 .8824) (Figure 1E).
CLL cells secreted high amounts of Par-4 compared with nor-
mal and stimulated spleen B cells (supplemental Figure 2A).
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Secreted Par-4 from CLL cells induced apoptosis of H460 lung
cancer cells, which was reduced by inclusion of anti–Par-4
antibody but not control immunoglobulin G (IgG) (supple-
mental Figure 2B). However, primary human CLL cells were not
sensitive to treatment with recombinant Par-4 or the SAC
domain, although they were all killed by OSU-2S, an FTY720
derivative (supplemental Figure 2C). Extracellular Par-4 re-
quires the receptor GRP78 to bind and induce extrinsic apo-
ptosis.27 CLL cells have lower levels of basal GRP78 protein
compared with other cell lines and this may be one reason why
CLL cells were not sensitive to Par-4–mediated apoptosis
(supplemental Figure 2D). Because intracellular Par-4 has been
shown to function by translocation into nucleus, we quantified
Par-4 levels in the cytoplasm and nucleus. CLL samples from
different individual Em-Tcl1 mice expressed Par-4 both in the
cytoplasm and the nucleus (supplemental Figure 2E). Addi-
tionally, we adoptively transferred Em-Tcl1 CLL cells into syn-
geneic C57BL/6J (WT) and Par-42/2 mice19 and detected
similar levels of Par-4 in the plasma as well as spleens of WT and
Par-42/2 mice 4 weeks after transfer (supplemental Figure 3).
Thus, Par-4 expressed by CLL cells is secreted in vitro and in
vivo, is cytotoxic to cell lines from solid tumors as shown
previously, and is able to translocate to the nucleus, which is
needed for intracellular Par-4 to induce apoptosis.27 Despite
the expression of functional Par-4, CLL cells develop de novo in
Par-41/1Tcl1 mice or grow unimpeded during adoptive transfer
into WT or Par-42/2 recipients.
Novel regulation of Par-4 through BCR signaling
in CLL
We tested the hypothesis that constitutively elevated expression
of Par-4 may be regulated by the well-known tonic BCR signaling
in CLL. Accordingly, Em-Tcl1 cells have increased phosphory-
lated Src family kinase (p-SFK) compared with both B-2 as well as
B-1 cell subsets (supplemental Figure 1C). Inhibition of Syk or Btk
with fostamatinib and ibrutinib, respectively, led to a decrease
in Par-4 protein accompanied by a decrease in p-Syk and p-Btk
and a decrease in viability, demonstrating the effectiveness of the
inhibitors in blocking their target kinases (Figure 2A-B; sup-
plemental Figure 4). In addition to the primary Em-Tcl1 CLL cells,
we tested the effect of dasatinib on 2 human-derived CLL cell
lines, Mec-1 and OSU-CLL,28,29 as well as primary human pe-
ripheral bloodCLL samples. Similar to the other kinase inhibitors,
dasatinib reduced the survival of all CLL cell models in a dose-
dependent manner (Figure 2C) and decreased p-SFK without
affecting levels of total Lyn kinase (Figure 2D). Reduced SFK
activity in Em-Tcl1 and Mec-1 CLL cells was accompanied by a
decrease in Par-4 protein and mRNA expression (Figure 2D-E),
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suggesting regulation at the transcript level. Minimal changes
in Syk, Btk, and Lyn total protein levels and the changes in
Par-4 protein and transcript levels detected at early time
points make it unlikely that decrease in Par-4 is due to death
of CLL cells after kinase inhibitor treatment. Due to the potential
off-target effects of kinase inhibitors, we also used lentiviral-
mediated shRNA to target Lyn, as it is required for BCR sig-
naling and survival of CLL cells.30-32 A 50% knockdown of Lyn
expression in Mec-1 cells led to reduced Par-4 protein and
mRNA expression (Figure 3A). Similar results were obtained
with the B-cell lymphoma cell line, LY-3, confirming that in-
hibition of Lyn leads to a decrease in Par-4 expression (sup-
plemental Figure 5).
To further establish the requirement for BCR, we used small-
interfering RNA (siRNA) to target CD79a (Iga) and tested the
effect on Par-4 expression in primary human CLL cells. Inhib-
iting CD79a expression reduces surface BCR expression and
the downstream activation of nonreceptor tyrosine kinases
required for BCR signaling, eliminating any pleiotropic effects
of kinase inhibition.4 siRNA transfection efficiency was;47% to
90% (supplemental Figure 6). We observed a decrease in
both CD79a and Par-4 expression by human CLL cells with
CD79a silencing, further confirming a novel regulation of Par-4
through BCR signaling (Figure 3B). We verified that silencing of
CD79a reduced IgM expression levels by flow cytometry,
leading to reduced Par-4 mRNA expression in multiple human
CLL cell samples (Figure 3C). Extracellular signal-regulated
kinase (ERK) signaling is known to be critical for B-cell sur-
vival and proliferation downstream of the BCR activation.33-35
Inhibition of ERK1/2 with SCH772984, a well-characterized
ERK2 inhibitor, led to a decrease in Par-4 protein expression
as well as a decrease in ERK phosphorylation (supplemental
Figure 7).36 Interestingly, there was no decrease in Par-4
expression in PC-3 cells after ERK inhibition (supplemental
Figure 7), suggesting that Par-4 is downstream of a survival and
proliferation pathway important in malignant B cells but not in
prostate cancer cells.
Par-4 regulates the growth of CLL cells in vitro and
in vivo
We evaluated the role of Par-4 in CLL by knocking down Par-4
in 2 CLL cell lines. There was a decrease in Par-4 protein and
mRNA expression after lentiviral shRNA-mediated knockdown
in Mec-1 cells (Figure 4A-B), which led to a decrease in overall
growth rate in vitro (Figure 4C; P5 .0024). Par-4 knockdownwith
shRNA led to reduced growth and thymidine incorporation in the
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OSU-CLL cell line compared with control shRNA treatment
(supplemental Figure 8A-C). Par-4 is known to inhibit Akt phos-
phorylation and reduce Bcl-2 levels,12,37 which were increased
in Par-4 knockdown Mec-1 cells confirming specific Par-4
knockdown (supplemental Figure 9). Subcutaneous injection of
control shRNA and Par-4 shRNA knockdown Mec-1 cells into
left or right flanks of NSGS mice, respectively, induced tumors
that were followed for 3 weeks. Par-4 knockdown Mec-1 cells
grew more slowly in vivo, mimicking the in vitro results
(Figure 4D left 2 panels). Injected tumors retained their knock-
down of Par-4 expression in vivo as shown through immunoblot
analysis (Figure 4D right panel). Additionally, NSG mice injected
with Par-4 shRNA-expressing OSU-CLL cells exhibited improved
survival time and delayed growth compared with mice injected
with OSU-CLL cells treated with control shRNA (supplemental
Figure 8D).
The unexpected result of Par-4 knockdown reducing the
growth rate of Mec-1 and OSU-CLL cells (Figure 4; supple-
mental Figure 8) and increasing the expression of known
prosurvival and antiapoptotic proteins (pAkt and Bcl-2; sup-
plemental Figure 9), led us to investigate whether knockdown
of Par-4 affected the cell cycle in CLL cells. Using 5 different
Par-4 shRNA and 4 control shRNA-expressing clones, we
showed that Par-4 knockdown Mec-1 cells had fewer cells
entering S phase but more cells in G1 phase, suggesting a
reduction in the G1-to-S transition (Figure 5A). Analysis of cell-
cycle regulatory proteins showed no change in Cdk1 expression
with only modest changes in Cdk2 and Cdk4 in Mec-1 cells upon
knocking down Par-4 (supplemental Figure 10). Expression of
p21 was increased in the Par-4 knockdown clones compared
with clones generated with control shRNA (Figure 5B). Quan-
titative reverse transcription PCR (qRT-PCR) confirmed the
protein expression results with a decrease in Par-4 mRNA and
a reciprocal increase in p21 mRNA expression in all 5 Par-4
knockdown clones of Mec-1 cells (Figure 5C-D). Additionally, using
human CLL cells, we confirmed that BCR-signaling inhibition
through CD79a silencing resulted in a decrease in Par-4 and a
reciprocal increase in p21 mRNA (Figure 5E).
To determine the effect of Par-4 in the development of CLL,
Em-Tcl1 mice were crossed with Par-42/2 mice and monitored for
CLL progression by measuring the CD51CD191 cells in the blood.
Mice were considered to have CLL if there was a distinct pop-
ulation of 15% to 20% CD51CD191 cells in the blood. Figure 6A
shows that CLL development is significantly delayed in Par-42/2
Tcl1 mice compared with the Par-41/1Tcl1 mice (P , .0003).
Figure 6B represents the survival analysis for Par-41/1Tcl1 and
Par-42/2Tcl1 mice. The average age of death of Par-41/1Tcl1 was
8.9 months vs the 11.97 months for Par-42/2Tcl1 mice (P , .05).
Immunoblot analysis of several tissues from the Par-42/2Tcl1
mice confirmed deficiency in Par-4, but positive expression of
Tcl1 (Figure 6C). Par-41/1Tcl1 mice expressed Par-4 and Tcl1 in
all tissues tested (supplemental Figure 11). Par-42/2Tcl1 spleen
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cells expressed higher levels of p21 protein compared with
Par-41/1Tcl1 spleen cells providing in vivo confirmation of the
p21 upregulation observed in vitro using Par-4 knockdown cell
lines (Figure 6D). For p21 to execute its function to block G1-to-S
transition, p21 has to translocate to the nucleus.38 Accordingly,
Par-42/2Tcl1 cells showed a robust increase of p21 in the nucleus
compared with Par-41/1Tcl1 cells, confirming that knockout of
Par-4 led to increased expression of functional p21 (supplemental
Figure 12).
Primary human CLL cells express high levels of
Par-4 regulated through BCR signaling
Characteristics of donor primary human CLL peripheral blood
samples are summarized in Table 1. CLL status was confirmed
through CD51CD191 staining by flow cytometry (supplemental
Figure 13). Immunoblot analysis showed constitutive BCR sig-
naling as reflected by p-SFK and total Lyn expression (Figure 7A).
CLL cell samples expressed significantly higher levels of Par-4
protein when compared with normal donor cells. We also com-
pared Par-4 expression in CLL cell samples to purified normal
B cells and confirmed that malignant B cells express higher levels
of Par-4 (Figure 7B). The Par-4 gene has been mapped to the
middle portion of chromosome 12, and trisomy 12 is associated
with ;16% of CLL cases.39-41 There does not appear to be a gene
dosage effect on Par-4 expression in trisomy 12 patients but
more samples are needed to confirm this conclusion (supple-
mental Figure 14A). Par-4 expression was found to be slightly
higher in the U-CLL patient samples compared with M-CLL but
this difference was not statistically significant (supplemental
Figure 14B). Survival of human CLL cells was also dependent on
BCR signaling as treatment with inhibitors of SFK, Syk, and Btk ki-
nases led to cell death (Figure 7C). Treatment of human CLL cells
with dasatinib, fostamatinib, and ibrutinib led to a decrease in
respective kinase activity and a downregulation of Par-4 protein
expression (Figure 7D; supplemental Figure 15). Thus, humanCLL
cells have constitutive BCR signaling and inhibition of this signaling
pathway regulates the expression of Par-4 that appears to promote
CLL growth.
Discussion
Previously, Par-4 has been defined as a well-known tumor sup-
pressor that is downregulated in several cancers and can selec-
tively induce and/or sensitize cancer cells to apoptosis.42 This
quality hasmade Par-4 an attractive potential therapeutic target in
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a variety of cancers, yet there are very few studies investigating its
regulation. In this study, wemade a surprising discovery that Par-4
expression in CLL is regulated by constitutive BCR signaling that
promotes the growth of CLL.
Both mouse Em-Tcl1 and primary human CLL cells express high
amounts of Par-4 compared with normal B-cell subsets and
whole peripheral blood samples, respectively. Increased ex-
pression levels led to concerns regarding whether Par-4
expressed in CLL cells was functional but we confirmed that
Par-4 was found in both the cytoplasm and the nucleus of CLL
cells and was secreted functionally to induce apoptosis of other
cancer cell lines. Previous studies have shown a direct inter-
action between p53 activation and elevated Par-4 secretion.43
p53 is mutated in the Mec-1 cell line, suggesting that Par-4
regulation is independent of p53 functional activity.44 Although
the interplay between p53 and p21 expression is well docu-
mented,45 due to the mutation status of p53, we hypothesize
that an alternative pathway may be activated with Par-4 loss
and the subsequent p21 induction. Preliminary studies in our
laboratory suggest that Par-4 is not mutated in Mec-1 cells.
Knockdown studies targeting Par-4 in CLL generated a distinct
phenotype that delayed the growth of CLL, which led us to
investigate roles of Par-4 other than its tumor suppressor
function.
Recently, cyclin-dependent kinase inhibitors are being investi-
gated for the treatment of leukemia due to their success in
solid tumors.46 Dinaciclib, a cyclin-dependent kinase inhibitor, re-
duced survival of CLL cells by inhibiting key oncogenic path-
ways.47 Our studies introduce Par-4 as a factor involved in the cell
cycle through connection with p21 in CLL cells as reduced ex-
pression of Par-4 led to a halt in the G1/S transition of the cell
cycle and a reciprocal induction of p21 expression. Interestingly,
CLL cells in the proliferation centers located in the lymph node
highly express cyclin D2, which is involved in the transition from
the G0/G1 to the S phase of cell cycle, whereas p21 is down-
regulated in actively cycling cells.48,49 Studies investigating the
interaction of Par-4 and cyclin D2 are warranted to elucidate the
potential progrowth role of Par-4 in CLL. Another study recently
investigated the relationship between Par-4 and p21 after in-
ducing endoplasmic reticulum stress with the treatment of a
natural product derivative, 3-Azido withaferin A (3-AWA).50 In-
duction of endoplasmic reticulum stress via 3-AWA treatment
in prostate and colon cancer cells increased Par-4 expression and
decreased p21. Results suggested that the loss of activated Akt
allowed for increase in Par-4 expression, which then promoted
apoptosis. The reduced expression of p21 after 3-AWA treat-
ment was found to be mediated by proapoptotic Jun N-terminal
kinase (JNK) activation. JNK is a key player in stress-induced
cell death in both normal and solid tumor cancers.51 Conversely,
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our laboratory has discovered that JNK is required for survival
and proliferation of malignant B-lymphoma cells, suggesting a
dual role for this kinase in solid vs lymphoid cancers,52 which
was shown to depend on the CARD11/Bcl10/Malt1 pathways
with negative regulation by DUSP4.53,54 The diverse roles that
JNK potentially plays in CLL vs epithelial cell tumors may be
contributing to the progrowth function of Par-4 in CLL via p21
suppression.
To determine the effect of Par-4 on CLL growth in vivo, we used
Par-42/2 mice, which were deficient for Par-4 in all tissues. In-
troduction of Par-4 deficiency delayed CLL development in the
Em-Tcl1 mice and also prolonged their survival compared with
Par-41/1Tcl1 mice. Because these are whole-body knockouts
for Par-4, the lack of Par-4 in the microenvironment and other
cell types could also be playing a role in the delayed CLL growth
observed. The Em-Tcl1mice lacking Par-4 had an average lifespan
of about 12 months, which was more than the Par-41/1Tcl1 mice,
although they developed CLL-like disease without indication of
other tumors previously observed in the Par-42/2 animals.10 The
characteristics of CLL in Par-42/2mice were indistinguishable from
Par-4–sufficient mice, demonstrating that Par-4 is not required
for CLL but appears to promote disease growth, when present.
Because CLL cells secrete Par-4, the CLL microenvironment
could be affected by Par-4, which is currently being investigated.
Additionally, we are generating B-cell–specific Par-42/2 mice to
further demonstrate its B-cell–intrinsic role.
For the first time here, we show that constitutive Par-4 expression
in CLL cells is regulated by BCR signaling by using small mol-
ecule inhibitors of upstream kinases activated by BCR as well
as by shRNA-mediated knockdown of Lyn kinase (supplemental
Figure 5) and siRNA targeting of CD79a (Figure 3B). When BCR
signaling is engaged, Src family and Syk protein kinases are
activated, which triggers activation of downstream signaling
networks that include the Ras-MAPK (ERK) pathway and the PI3K
pathway.33 Targeting ERK1/2 in Em-Tcl1 CLL cells resulted in a
decrease in Par-4 expression, further confirming that Par-4 is
regulated by survival signaling in malignant CLL cells. Thus,
high levels of Par-4 coexisted with constitutive ERK activation in
CLL cells, which is once again different from fibroblasts wherein
Par-4 was shown to block ERK2 expression to prevent Ras
transformation and Par-4 itself was inhibited by the Ras-MEK-
ERK pathway.55 PC-3 prostate cancer cells also exhibit ERK1/2
activation despite expressing high levels of Par-4, which appears
to be due to signaling upstream of ERK1/2 in PC-3 cells. PKCa
and epidermal growth factor receptor signaling have both been
found to be responsible for ERK1/2 signaling in PC-3 cells and
could be masking the effect of ERK inhibition by Par-4.56 PKCa
is found to be variably expressed in CLL cells and potentially
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could not compensate for the inhibition of ERK1/2 signaling on
Par-4 expression,57 suggesting that Par-4 regulation by the Ras-ERK
pathway may be tissue specific.
In summary, our studies demonstrate that constitutive Par-4
expression is regulated by the well-known tonic signaling via
BCR in CLL cells, showing, for the first time, regulation of Par-4
expression by a cell surface receptor and that the constitutively
expressed Par-4 is functional. Furthermore, our studies suggest
that the tumor suppressor Par-4may have a novel progrowth role
in the context of CLL. Because Par-4 enhances the growth of CLL
cells, it may be beneficial to CLL patients to inhibit Par-4. Current
Table 1. Human CLL patient information
Patient no. Age, y Treated CD381 Zap701 IgVH mutation Cytogenetics WBC, 3 109/L
UK hCLL
1 76 No Positive U-CLL Trisomy 12 19.8
2 82 No Negative Negative M-CLL 20.7
3 56 No U-CLL
4 36 No Negative M-CLL 13q deletion 38.3
6 46 No Negative Negative M-CLL 13q deletion 41
7 52 Yes M-CLL 15.2
8 69 No Positive M-CLL Normal 29
9 57 Yes U-CLL 40
10 62 Yes M-CLL 11.7% 17p deleted cells 83.7
11 69 No M-CLL Trisomy 12, 13q deletion 30.2
13 70 No M-CLL 17.4
14 63 No Positive Positive M-CLL Trisomy 12 34.8
15 53 Yes Positive Positive U-CLL 13q deletion 12.1
16 55 Yes M-CLL 6
17 76 Yes M-CLL 36.6
18 80 Yes U-CLL 142
20 57 No U-CLL 7.4
21 78 No M-CLL 45.9
22 74 No Negative Negative M-CLL 11.3
23 77 Yes* Negative Negative M-CLL 11
24 71 No Negative Negative M-CLL 7.7
25 70 No Negative Negative M-CLL 23
26 62 No Negative Positive M-CLL 62.5
27 64 No Negative Positive U-CLL 9.4
28 58 Yes* Negative Positive U-CLL 8.4
29 80 Yes* Positive Positive U-CLL 39.6
30 52 No Negative Positive U-CLL 68.2
31 66 No Negative Negative U-CLL 20.4
OSU hCLL
1 40 M-CLL 13q deletion 88.2
2 59 M-CLL 13q deletion 22.6
3 M-CLL 13q deletion 99.1
4 51 M-CLL Trisomy 12 148.8
5 71 U-CLL 138
6 U-CLL 17p deletion; 13q deletion 152
7 U-CLL 13q deletion; 11q deletion 196.6
8 57 U-CLL 13q deletion; 2.5% trisomy 12 38.2
9 M-CLL 106.9
10 M-CLL 13q deletion 221.3
11 61 M-CLL 78.2
12 68 M-CLL 13q deletion 170.9
13 72 U-CLL Trisomy 12 135.2
14 61 U-CLL 17p deletion; 13q deletion 87
15 55 U-CLL 157.2
16 67 U-CLL Trisomy 12 330.7
Blank cells indicate that relevant information is not available. Total peripheral white blood cell (WBC) counts at the time of collection are indicated. Cytogenetics, CD381, Zap701 are indicated
if known through previous diagnosis or by flow cytometry. CD381 distinction was determined by.30% CD381 cells of leukemic clone.23,58 Patient samples were collected at the University of
Kentucky Markey Cancer Center (UK hCLL) or as indicated at The Ohio State (OSU hCLL) Brown Comprehensive Cancer Center.
*Patient has received previous therapy but not on current treatment.
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therapeutics for CLL target the BCR-signaling pathway, which
may inadvertently reduce Par-4 expression. In future studies,
it would be interesting to see whether combination therapy
involving Par-4 inhibition would bemore effective than inhibition
of BCR signaling alone, especially for patients who develop
resistance to such therapies.
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